12:00 AM
 | 
Mar 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

XL647: Phase III started

Kadmon began a double-blind, placebo-controlled, U.S. Phase III trial to compare once-daily 300 mg oral KD019 vs. once-daily 150 mg oral Tarceva erlotinib in about 620 patients with stage IIIB/IV NSCLC who have progressed after first- or second-line chemotherapy. The trial will use the VeriStrat test from Biodesix...

Read the full 249 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >